TxCell presents immuno-monitoring results of its phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease
Results supportive of Ovasave(R) mechanism of action were presented at the seventh European Crohn’s and Colitis Organization (ECCO) meeting in Barcelona
23-Feb-2012 -
TxCell SA announced immuno-monitoring results of the phase I/II study in Crohn’s disease (CATS1) with its leading product candidate Ovasave(R). The results of this study, performed on 20 patients, were presented at the seventh European Crohn’s and Colitis Organization meeting, in Barcelona.The ...
Crohn's disease
phase I studies
phase II studies